Innovative methods to assess upper limb strength and function in non-ambulant Duchenne patients.
Servais L, Deconinck N, Moraux A, Benali M, Canal A, Van Parys F, Vereecke W, Wittevrongel S, Mayer M, Desguerre I, Maincent K, Themar-Noel C, Quijano-Roy S, Serari N, Voit T, Hogrel JY.
Neuromuscul Disord. 2013. 23(2) : 139-48.
Development of new tools to precisely assess pinch (MyoPinch), grip (MyoGrip), wrist flexion and extension (MyoWrist) strength in children with dystrophy muscular dystrophy (DMD). Comparative analyzes were performed for both these new tools and tests already validated and used in clinical practice, such as MFM, in 30 non ambulant patients with DMD and in 30 healthy volunteers matched for age. With the exception of Myo-Wrist may pose problems of interpretation in cases of significant contractures of the wrist, the other tools are interesting, reproducible and correlate well with the measurement methods already used.
Keywords: Outcome measures, Duchenne muscular dystrophy, Upper limb, Functional test, Strength
Articles dans les revues scientifiques
Corticosteroids in Duchenne muscular dystrophy: impact on the motor function measure sensitivity to change and implications for clinical trials
Schreiber A, Brochard S, Rippert P, Fontaine-Carbonnel S, Payan C, Poirot I, Hamroun D, Vuillerot C Dev Med Child Neurol. 2018. 60(2):185-191. The aim of the study was to monitor the evolution of the motor function of ambulatory patients with Duchenne muscular...
Quantitative muscle MRI to follow up late onset Pompe patients: a prospective study
Figueroa-Bonaparte S, Llauger J, Segovia S, Belmonte I, Pedrosa I, Montiel E, Montesinos P, Sánchez-González J, Alonso-Jiménez A, Gallardo E, Illa I, Díaz-Manera J ; Spanish Pompe group.Sci Rep. 2018. 18;8(1):10898. In this study, 32 Late onset Pompe disease patients...
Turkish version of the Motor Function Measure Scale (MFM-32) forneuromuscular diseases: a cross-cultural adaptation, reliability, and validity study
Inal HS, Tarakçi E, Tarakçi D, Aksoy G, Mergen Kiliç S, Beser H, Beser Ç, Özdinçler AR, Durmus Tekçe H, Parman FY, Deymeer F, Oflazer ZP Turk J Med Sci. 2017. 19;47(6):1826-1833. Study aiming to analyze the reliability and validity of a translation and cultural...
Long term longitudinal study of muscle function in patients with glycogen storage disease type IIIa
Decostre V, Laforêt P, De Antonio M, Kachetel K, Canal A, Ollivier G, Nadaj-Pakleza A, Petit FM, Wahbi K, Fayssoil A, Eymard B, Behin A, Labrune P, Hogrel JY Mol Genet Metab. 2017. 122(3):108-116. Preliminary results of a longitudinal study assessing in patients with...
Adding quantitative muscle MRI to the FSHD clinical trial toolbox
Mul K, Vincenten SCC, Voermans NC, Lemmers RJLF, van der Vliet PJ, van der Maarel SM, Padberg GW, Horlings CGC, van Engelen BGM Neurology. 2017. 14;89(20):2057-2065. Assessment from a cohort of 140 patients with facioscapulohumeral muscular dystrophy (FSHD) of...
Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial
Bertini E, Dessaud E, Mercuri E, Muntoni F, Kirschner J, Reid C, Lusakowska A, Comi GP, Cuisset JM, Abitbol JL, Scherrer B, Ducray PS, Buchbjerg J, Vianna E, van der Pol WL, Vuillerot C, Blaettler T, Fontoura P; Olesoxime SMA Phase 2 Study Investigators Lancet Neurol....